HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
EVFM [NASD]
Evofem Biosciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-18.97 Insider Own2.30% Shs Outstand163.14M Perf Week233.23%
Market Cap13.51M Forward P/E- EPS next Y-1.16 Insider Trans94.32% Shs Float155.32M Perf Month208.36%
Income-192.10M PEG- EPS next Q-1.35 Inst Own13.50% Short Float1.28% Perf Quarter-80.38%
Sales11.40M P/S1.19 EPS this Y25.70% Inst Trans-13.10% Short Ratio0.12 Perf Half Y-83.33%
Book/sh-11.55 P/B- EPS next Y46.40% ROA-303.30% Target Price22.10 Perf Year-94.10%
Cash/sh- P/C- EPS next 5Y- ROE272.20% 52W Range0.28 - 18.60 Perf YTD-81.00%
Dividend- P/FCF- EPS past 5Y22.60% ROI- 52W High-94.25% Beta0.11
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin59.50% 52W Low289.09% ATR0.15
Employees119 Current Ratio0.10 Sales Q/Q290.90% Oper. Margin- RSI (14)65.86 Volatility42.52% 18.02%
OptionableYes Debt/Eq- EPS Q/Q65.90% Profit Margin- Rel Volume28.97 Prev Close1.07
ShortableYes LT Debt/Eq- EarningsMay 04 AMC Payout- Avg Volume17.20M Price1.07
Recom2.20 SMA20184.68% SMA50-15.11% SMA200-82.30% Volume343,590,688 Change0.00%
Oct-14-21Downgrade Morgan Stanley Equal-Weight → Underweight $0.80
Oct-02-20Initiated Stifel Buy $5
Aug-20-20Initiated Morgan Stanley Equal-Weight $3
Jun-08-20Initiated Piper Sandler Overweight $11
Oct-16-19Resumed Cantor Fitzgerald Overweight $9
Jun-28-22 05:31PM  
2 Contraceptive Stocks That Could Benefit From Roe v. Wade Reversal
TipRanks
06:48AM  
Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®
PR Newswire
Jun-27-22 02:13PM  
Evofem's stock is still up after Friday's Supreme Court decision
MarketWatch +187.71%
02:12PM  
Evofem's stock is still soaring after Friday's Supreme Court decision
MarketWatch
Jun-24-22 12:10PM  
Evofem's stock jumps 30% after Supreme Court decision on Roe v. Wade
MarketWatch +16.95%
Jun-16-22 08:46AM  
Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data
PR Newswire
Jun-07-22 08:15AM  
Traders News Source Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
ACCESSWIRE
Jun-02-22 08:46AM  
US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years
PR Newswire
May-20-22 09:13AM  
Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering
PR Newswire -63.17%
May-19-22 05:59PM  
Evofem Biosciences Announces Proposed Public Offering
PR Newswire +6.80%
May-10-22 08:46AM  
Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®
PR Newswire -7.44%
May-06-22 08:46AM  
Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial
PR Newswire -15.46%
May-05-22 09:00AM  
Evofem Biosciences Announces 1-for-15 Reverse Stock Split
PR Newswire -32.93%
May-04-22 04:01PM  
Evofem Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
PR Newswire
Apr-27-22 08:46AM  
Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services
PR Newswire
Apr-26-22 08:46AM  
Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting
PR Newswire -6.03%
Apr-25-22 09:00AM  
Evofem Biosciences to Report First Quarter 2022 Results and Provide Corporate Update on Wednesday, May 4, 2022
PR Newswire
Apr-19-22 06:52AM  
Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem's Phase 3 AMPOWER Clinical Trial
PR Newswire
Apr-11-22 06:48AM  
Evofem Announces Karina Fedasz as Company's New Head of Business Development
PR Newswire
Apr-07-22 06:50AM  
Nasdaq Accepts Evofem Plan to Regain Listing Compliance
PR Newswire -9.54%
Mar-31-22 01:00PM  
Evofem Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women at the 2022 Academy of Managed Care Pharmacy Annual Meeting
PR Newswire -6.31%
Mar-04-22 06:48AM  
Evofem Completes Enrollment in EVOGUARD Phase 3 Clinical Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women
PR Newswire -10.20%
Mar-03-22 04:00PM  
Evofem Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
PR Newswire -8.12%
Mar-01-22 10:22AM  
Shareholders in Evofem Biosciences (NASDAQ:EVFM) are in the red if they invested a year ago
Simply Wall St.
Feb-17-22 09:00AM  
Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022
PR Newswire
Feb-09-22 09:00AM  
FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences
PR Newswire
Feb-08-22 09:00AM  
Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022
PR Newswire
Jan-21-22 05:38PM  
Callan Capital, LLC Buys Schwab Fundamental U.S. ...
GuruFocus.com
Jan-19-22 09:00AM  
Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021
PR Newswire +22.86%
Jan-12-22 10:18AM  
Why Are Evofem Biosciences Shares Rising On Wednesday?
Benzinga +9.11%
06:00AM  
Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women
PR Newswire
Jan-04-22 07:00AM  
Evofem Biosciences to Present at H.C. Wainwright BioConnect Conference
PR Newswire
Dec-21-21 12:15AM  
Evofem Biosciences Inc (EVFM) CEO Saundra L Pelletier Bought $51,300 of Shares
GuruFocus.com +16.67%
Dec-16-21 07:00AM  
Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention
PR Newswire
07:00AM  
Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention
CNW Group
Dec-09-21 08:00AM  
Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021
PR Newswire +12.94%
Dec-08-21 06:30AM  
Evofem Biosciences to Adjourn Special Meeting of Stockholders on December 8, 2021
PR Newswire
Nov-30-21 08:00AM  
Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate
PR Newswire
Nov-22-21 06:50AM  
Evofem Biosciences Successfully Extends Cumulative Net Sales Covenant Timing to June 30, 2023
PR Newswire
Nov-19-21 07:00AM  
Evofem Biosciences to Participate in Piper Sandler 33rd Annual Healthcare Conference
PR Newswire
Nov-15-21 04:00PM  
Evofem Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Update
PR Newswire
Nov-10-21 07:00AM  
Evofem Biosciences Announces Regulatory Submission in Mexico for Its Hormone-Free Contraceptive
PR Newswire
Nov-04-21 08:00AM  
Evofem Biosciences to Participate in Stifel 2021 Virtual Healthcare Conference
PR Newswire
Oct-28-21 08:00AM  
Evofem Biosciences to Report Third Quarter 2021 Results and Provide Corporate Update on Monday, November 15, 2021
PR Newswire
Oct-20-21 08:00AM  
"House Rules" Delivers Strong Initial Results and Drives Phexxi Growth
PR Newswire
Oct-12-21 06:31AM  
Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock
PR Newswire
Oct-08-21 08:00AM  
Evofem Biosciences Commends House of Representatives Leaders for Action to Ensure Coverage for the Full Range of Contraceptives Under ACA
PR Newswire
Sep-30-21 08:00AM  
Evofem Biosciences to Present at LD Micro Investor Conference on October 12, 2021
PR Newswire
Sep-27-21 08:00AM  
Evofem Biosciences Announces Publication in Peer-Reviewed Journal Advances in Therapy
PR Newswire
Sep-16-21 08:00AM  
Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator
PR Newswire
Sep-09-21 08:00AM  
Emmy® Award Winner Annie Murphy Partners with Evofem Biosciences to Talk Sex, Contraception, and Why She Chose Phexxi®
PR Newswire
Sep-02-21 09:03AM  
Evofem Biosciences (NASDAQ:EVFM) shareholders have endured a 78% loss from investing in the stock three years ago
Simply Wall St.
Sep-01-21 08:00AM  
Evofem Biosciences to Participate in Investor Conferences
PR Newswire
Aug-31-21 12:00PM  
2 Strong Buy Penny Stocks That Offer Massive Potential Gains
TipRanks +13.30%
Aug-11-21 04:27PM  
Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update
PR Newswire
Jul-28-21 08:00AM  
Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021
PR Newswire +5.29%
Jul-14-21 08:00AM  
Early Look at Second Quarter Metrics for Phexxi® Reveals Strong Growth
PR Newswire
Jun-01-21 09:00AM  
Evofem Biosciences to Present at Jefferies Virtual Healthcare Conference 2021
PR Newswire
May-25-21 08:00AM  
Evofem Biosciences to Present at LD Micro Invitational XI on Tuesday, June 8, 2021
PR Newswire
May-21-21 06:50AM  
Evofem Biosciences Announces Closing of $50 Million Public Offering
PR Newswire
May-18-21 09:06AM  
Evofem Biosciences Stock Plunges On Raising $50M Via Equity At 22% Discount
Benzinga -34.17%
May-17-21 11:02PM  
Evofem Biosciences Announces Pricing of $50 Million Public Offering
PR Newswire
04:02PM  
Evofem Biosciences Announces Proposed Public Offering
PR Newswire
08:00AM  
New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021
PR Newswire
May-12-21 04:19PM  
Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
Benzinga
09:00AM  
Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women
PR Newswire
May-06-21 04:01PM  
Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update
PR Newswire -5.43%
02:30PM  
Evofem Biosciences, Inc. to Host Earnings Call
ACCESSWIRE
Apr-28-21 11:00AM  
Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting
PR Newswire
Apr-22-21 08:00AM  
Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021
PR Newswire
Apr-21-21 08:00AM  
Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum
PR Newswire +10.56%
Mar-29-21 04:05PM  
Evofem Biosciences Announces Closing of Public Offering of Common Stock
PR Newswire -6.42%
Mar-25-21 07:58AM  
The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut
Benzinga -26.61%
Mar-24-21 10:00PM  
Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock
PR Newswire -9.34%
04:00PM  
Evofem Biosciences Announces Proposed Public Offering of Common Stock
PR Newswire
Mar-17-21 08:00AM  
Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact
PR Newswire
Mar-16-21 08:00AM  
Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention
PR Newswire
Mar-06-21 03:05AM  
What Type Of Shareholders Make Up Evofem Biosciences, Inc.'s (NASDAQ:EVFM) Share Registry?
Simply Wall St.
Mar-05-21 01:00PM  
Why Evofem Biosciences Stock Is Falling Today
Motley Fool -30.28%
10:38AM  
ROCE Insights For Evofem Biosciences
Benzinga
Mar-04-21 04:00PM  
Evofem Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
PR Newswire -9.17%
02:30PM  
Evofem Biosciences, Inc. to Host Earnings Call
ACCESSWIRE
Feb-23-21 08:00AM  
Evofem Biosciences to Present at H.C. Wainwright Global Life Sciences Conference
PR Newswire -7.88%
Feb-18-21 08:00AM  
Evofem Biosciences to Report Fourth Quarter and Year-End 2020 Results and Provide Corporate Update on Thursday, March 4, 2021
PR Newswire
Feb-16-21 08:00AM  
Evofem Biosciences Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of Phexxi®, A Non-Hormonal Birth Control Option for Women
PR Newswire
Feb-04-21 09:00AM  
Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with Cancer
PR Newswire +6.15%
Jan-12-21 09:05AM  
Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021
PR Newswire
Dec-22-20 07:00AM  
Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi® Effective January 1, 2021
PR Newswire +12.56%
Dec-21-20 09:00AM  
Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
PR Newswire
Dec-17-20 07:00AM  
Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea
PR Newswire
Dec-12-20 03:12PM  
Is EVFM A Good Stock To Buy Now?
Insider Monkey
Dec-11-20 08:00AM  
Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi®
PR Newswire
Dec-03-20 07:00AM  
The U.S. Department of Veterans Affairs Awards Contract to Evofem Biosciences for Phexxi®
PR Newswire
Nov-20-20 08:30AM  
Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
PR Newswire
Nov-12-20 08:30AM  
Evofem Biosciences to Present at Stifel Virtual Healthcare Conference
PR Newswire
Nov-09-20 11:00PM  
Evofem Biosciences, Inc. (EVFM) Q3 2020 Earnings Call Transcript
Motley Fool
04:01PM  
Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
PR Newswire
03:15PM  
Evofem Biosciences, Inc. to Host Earnings Call
ACCESSWIRE
Oct-27-20 08:00AM  
Evofem Biosciences to Report Third Quarter 2020 Results and Provide Corporate Update on Monday, November 9, 2020
PR Newswire
Oct-26-20 09:00AM  
Evofem Biosciences to Participate in Virtual Investor KOL Roundtable
PR Newswire
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PELLETIER SAUNDRA LChief Executive OfficerMay 27Buy0.35141,00049,702236,722May 31 08:55 AM
File Justin J.Chief Financial OfficerDec 20Buy0.3740,59415,020480,982Dec 20 04:20 PM
Fitzpatrick Alexander AGeneral Counsel and SecretaryDec 20Buy0.3925,0009,725336,422Dec 20 04:20 PM
PELLETIER SAUNDRA LChief Executive OfficerDec 20Buy0.38135,00050,625985,837Dec 20 04:19 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.